Skip to content
Research library

Clinical research overview

This library brings together peer-reviewed studies on Mesenchymal Stem Cells (MSCs) across a wide range of medical indications. Each study contributes to a deeper understanding of how MSCs support repair, regeneration, and immune balance in the body.
Crohn's disease Aging frailty Osteoarthritis
Acute respiratory disease syndrome Graft versus host disease (GvHD) Multiple sclerosis Liver cirrhosis Diabetes type II Diabetes type I Chronic low back pain Chronic obstructive pulmonary disease (COPD) Alzheimer's disease Rheumatoid arthritis

Alzheimer's disease

Ongoing studies are examining Mesenchymal Stem Cells (MSCs) in Alzheimer's disease, with attention to clinical feasibility, safety considerations, and their possible impact on neuroinflammatory processes and neuronal health. Alzheimer's disease represents the leading cause of dementia, characterized by progressive memory loss, cognitive decline, and behavioral changes. The condition involves abnormal protein accumulation in the brain, resulting in neuron and synapse loss. Current treatments offer temporary symptom relief and may slow progression without halting disease advancement. Research into MSC applications for Alzheimer's remains preliminary. Scientists are exploring whether immunomodulatory and neuroprotective properties could support brain function maintenance. Although findings are early-stage, investigations are building scientific evidence for potential novel dementia treatment approaches.

Results and insights from a phase I clinical trial of Lomecel-B for Alzheimer's disease

Mark Brody, et al.
The researchers hypothesized that Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapeutic candidate for Alzheimer's disease (AD), is safe and potentially disease-modifying via pleiotropic mechanisms of action.
More
Read study

Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer's disease dementia: a phase I clinical trial

Hee Jin Kim, et al.
CSF samples collected 1 day after hUCB-MSC injections showed reduced levels of total tau, phosphorylated tau, and Aβ42. However, levels increased 4 weeks after transplantation, indicating a short duration of therapeutic effects. Additionally, Expression levels of Galactin-3, sICAM-1, progranulin, and GDF-15 increased initially but dropped significantly within 4 weeks.
More
Read study